Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Latest news

Read or download our press releases for all latest news about our company, research & development activities and updates for investors. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with Oxurion associates. Be sure to check in regularly for the latest Oxurion press releases or just subscribe to our mailing list to receive regular updates.

Subscribe to our mailing list

9 May 2022
Clinical update; THR-687
Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)

Leuven, BELGIUM, Boston, MA, US – MAY 9,2022 – 8:30 AM CET – ...

6 May 2022
Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022
Leuven, Belgium, Boston, MA, US – May 6, 2022 – 07.00 PM CET –...
5 May 2022
Event
Oxurion to Participate in Upcoming Conferences

Leuven, BELGIUM, Boston, MA, US – MAY 5, 2022 –...

3 May 2022
Clinical update; THR-687
Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Leuven, BELGIUM, Boston, MA, US – May 3, 2022 – 7:10 PM CET –...

29 Apr 2022
Regulated information - denominator
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

Negma Group has converted 230 convertible bonds in Oxurion resulting in a EUR 575,000...

11 Apr 2022
Clinical update; THR-687
Oxurion Announces Upcoming Preclinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Leuven, BELGIUM, Boston, MA, US – 11 April 2022 – 7.00 AM CET –...

1 Apr 2022
Regulated information
Oxurion Announces Extraordinary and Annual Shareholders’ Meetings

Leuven, Belgium, Boston, MA, US - April 1, 2022 – 07....

Archive

Media contact

Oxurion is committed and engaged to communicate openly with all of its stakeholders. For any media enquiries, comments or questions about Oxurion, please contact our Investor Relations & Corporate Communications team:

Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 16 751 310

Info@oxurion.com